Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis

Arthritis & Rheumatology  |  September 20, 2024

Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.

Filed under:Axial SpondyloarthritisConditions Tagged with:Anti-infliximab antibodiesArthritis & RheumatologyAS Resource Centeraxial spondyloarthritis (SpA)infliximab

Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars

From the College  |  May 5, 2024

Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.

Filed under:InsuranceLegislation & Advocacy Tagged with:ACR advocacyBiosimilarsinfliximab

UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars

From the College  |  April 6, 2024

On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.

Filed under:InsuranceLegislation & Advocacy Tagged with:Biosimilarsdrug pricing

Therapeutic Drug Monitoring May Offer Little Benefit to Patient Remission Rates During Infliximab Induction Therapy

Lara C. Pullen, PhD  |  August 9, 2021

Although rheumatologists prescribe tumor necrosis factor inhibitors (TNFi’s) to treat several rheumatic diseases, they recognize immunogenicity influences the efficacy and safety of TNFi’s. Example: The formation of anti-drug antibodies can affect infusion reactions and cause low-serum drug levels and therapeutic failure. The induction phase is a period of high incidence of immunogenicity, and observational data…

Filed under:Drug Updates Tagged with:infliximabtherapeutic drug monitoringTNF inhibitorTNFitumor necrosis factor inhibitor (TNFi)

Therapeutic Drug Monitoring Has Little Value During Infliximab Induction

Reuters Staff  |  May 12, 2021

NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…

Filed under:Conditions Tagged with:infliximabinfliximab inductiontherapeutic drug monitoring

UnitedHealthcare Designates Avsola, Inflectra Preferred Infliximab Products

From the College  |  February 8, 2021

On Feb. 1, UnitedHealthcare enacted a new policy designating Avsola and Inflectra as the preferred infliximab products for UHC commercial plans. ACR leaders have urged UHC to allow existing patients to continue on their current medication.

Filed under:American College of RheumatologyBilling/CodingBiologics/DMARDs Tagged with:Biosimilarsinfliximab biosimilarnon-medical switchingUnitedHealthCare (UHC)

EU Approves Remsima SC, a Biosimilar to Infliximab

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2020

Subcutaneous CT-P13 (Remsima SC), biosimilar to infliximab, will soon be available in the E.U. to treat adults with rheumatoid arthritis…

Filed under:Biologics/DMARDsDrug Updates

FDA Approves Amgen’s Infliximab Biosimilar Treatment

Reuters Staff  |  December 10, 2019

(Reuters)—The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab), according to the regulator’s website. The biosimilar, Avsola (infliximab-axxq), has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. The label for the…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Avsolainfliximabinfliximab biosimilarinfliximab-axxqRemicadeREMICADE (infliximab)U.S. Food and Drug Administration (FDA)

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

Will Boggs MD  |  April 22, 2019

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…

Filed under:Biologics/DMARDsDrug Updates Tagged with:biosimilar CT-P13inflammatory bowel disease (IBD)infliximabinfliximab biosimilar

Study Supports Safety of Infliximab in Pregnancy

Reuters Staff  |  July 31, 2018

NEW YORK (Reuters Health)—New registry data should help reassure women with Crohn’s disease (CD) who need to continue infliximab during pregnancy that it won’t harm their baby. “The clinical condition of infants born to women with gestational infliximab exposure was similar to those without exposure,” the study team reports online July 19 in the American…

Filed under:Conditions Tagged with:Crohn's diseaseinfantsinfliximabpregnancy

  • 1
  • 2
  • 3
  • …
  • 40
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences